Figures
Abstract
Objective
The clinical utilization of non-invasive prenatal testing (NIPT) for identification of fetal aneuploidies is expanding worldwide. The aim of this study was to gain an increased understanding of pregnant women’s awareness, attitudes, preferences for risk information and decision-making concerning prenatal examinations with emphasis on NIPT, before its introduction into Swedish healthcare.
Method
Pregnant women were recruited to fill in a questionnaire, including multiple-choice questions and Likert scales, at nine maternity clinics located in different areas of Stockholm, Sweden.
Results
In total, 1,003 women participated in the study (86% consent rate). The vast majority (90.7%) considered examinations aiming to detect fetal abnormalities to be good. Regarding NIPT, 59.8% stated that they had heard about the method previously, yet 74.0% would like to use the test if available. The main factor affecting the women’s decision to undergo prenatal chromosomal screening was worry about the baby’s health (82.5%), followed by the urge to have as much information as possible about the fetus (54.5%). Most women (79.9%) preferred to receive NIPT information orally.
Citation: Sahlin E, Nordenskjöld M, Gustavsson P, Wincent J, Georgsson S, Iwarsson E (2016) Positive Attitudes towards Non-Invasive Prenatal Testing (NIPT) in a Swedish Cohort of 1,003 Pregnant Women. PLoS ONE 11(5): e0156088. https://doi.org/10.1371/journal.pone.0156088
Editor: Kelvin Yuen Kwong Chan, Hospital Authority, CHINA
Received: February 18, 2016; Accepted: May 9, 2016; Published: May 19, 2016
Copyright: © 2016 Sahlin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This research was made possible by a grant from Stockholm County Council and supported by the Swedish Foundation for Humanities and Social Sciences (Riksbankens Jubileumsfond, http://www.rj.se/) under grant M13-0260:1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Non-invasive prenatal testing (NIPT) for identification of chromosomal aneuploidies is the most recent addition to the growing palette of fetal examination methods available today. The test is possible because cell-free fetal DNA is present in maternal blood during pregnancy [1]. A fetal trisomy will give rise to a small gain in DNA fragments from the trisomic chromosome, which can be detected with high accuracy using massive parallel sequencing [2–7]. The sensitivity and specificity as well as the negative predictive value of the method is >99% for trisomy 21 (Down syndrome), with slightly lower performance for trisomy 13 and 18 [8–11]. However, the positive predictive value varies depending on the prevalence of trisomy in the population being tested, and is not higher than 50–80% in an unselected pregnant population [8,9,12]. As a consequence, NIPT is not considered a diagnostic test, and invasive testing by amniocentesis or chorionic villus sampling (CVS) is therefore recommended to confirm the presence of a chromosomal abnormality in case of a positive test result [13]. Although recent studies indicate that the invasive tests are very safe [14,15], they have traditionally been burdened with a non-negligible risk of miscarriage [16,17]. Additionally, the invasive procedure per se is often experienced as unpleasant, as well as it requires fetal medicine experts to perform the test. Therefore, the invasive tests have never been an option for large-scale testing, and screening methods have been developed to identify women at high risk of fetal aneuploidy. As NIPT has a much higher accuracy compared with current other screening methods, many invasive tests could be avoided if NIPT was used as the primary screening [12]. Still, questions have arisen regarding how to best implement NIPT into clinical practice. Previous studies have shown positive attitudes towards NIPT among both the public and pregnant women [18–21]. However, as the test only requires a blood sample, there are concerns that it will be taken without sufficient consideration [22,23], that its accuracy in combination with the simplicity of the test may lead to normalization of selective abortions [24], and that people with physical and intellectual disabilities might face an increased stigmatization in society [25,26]. It is of great importance to provide expectant parents with accurate information concerning prenatal examinations, associated risks, and potential consequences of a positive test result. However, this task might be challenging for health professionals as risk information is highly complex [27], and additionally, risk perception varies depending on factors such as personal background, gender and socio-economic status, and is highly influenced by emotions and affect [28].
This study was performed in Stockholm before, but in close proximity to, the introduction of NIPT into Swedish healthcare. At the time of data collection, pregnant women in Stockholm were offered the first trimester combined test (FCT), and 64% took the test (data from 2014) [29]. However, NIPT was available at a few private clinics at a cost of approximately €1,000 and NIPT ads could be found regularly in local newspapers. The aim was to gain an increased understanding of pregnant women’s awareness, attitudes, preferences about risk information and decision-making concerning prenatal examinations with emphasis on NIPT, as well as to gain knowledge about how this new method would be accepted by the potential users. Additionally, attitudes towards having a child with a chromosomal abnormality were studied, as well as the women’s self-perceived likelihood for that event to occur. A large cohort of 1,003 pregnant women was included to obtain a substantial material that could serve as valuable input when presenting information prior to prenatal examinations.
Methods
The questionnaire
The questionnaire used for data collection was study specific and developed by the research group. The group, which was interdisciplinary, consisted of a biomedical scientist, a consultant and two senior consultants in Clinical Genetics as well as a midwife experienced in questionnaire development within this research area. The questionnaire included background questions (age, mother tongue, educational level, gestational week, parity, previous miscarriages) as well as multiple choice questions and Likert scales covering attitudes, knowledge, preferences for risk information and decision-making regarding prenatal examinations, with emphasis on NIPT. One question regarding attitudes towards prenatal examinations had been used in previous studies [30]. The questionnaire also covered attitudes towards having a child with a chromosomal abnormality, and the self-perceived likelihood of that event to occur. The questionnaire was available in Swedish, designed to be quick and easy to fill in, and took approximately five minutes to complete.
Study participants and procedure
Pregnant women in any week of gestation were recruited to participate in the study. They were recruited in waiting rooms of nine different maternity clinics located in different areas of Stockholm, selected to represent a broad socioeconomic variety of the participants. All participants were provided oral and written information about the study, whereupon they filled in the questionnaire directly in the waiting room. The questionnaire was filled in anonymously, and all participants had the possibility to withdraw from the study by not handing in the questionnaire. To understand women’s current awareness and spontaneous attitudes, no background information was given regarding the prenatal examination methods covered in the questions. However, the researchers were available to answer questions at all times during the completion of the questionnaires. The study was approved by the Regional Ethical Review Board in Stockholm (DNR 2014/1817-31/4). All data were collected between January 27 and June 3, 2015, i.e. before the introduction of NIPT into Swedish healthcare.
Statistical analysis
All calculations were performed using the IBM Statistical Package for the Social Sciences (SPSS) version 22. Descriptive statistics were used to extract answer frequencies to the questions in the questionnaire. Fisher’s exact test was used to assess statistically significant differences in answer proportions between subgroups in case of binary answer alternatives, and the Chi2 test was used in case of multiple answer alternatives. The significance level was set to p<0.05. Five-point Likert scales were compressed to two or three categories to avoid small cell sizes.
Results and Discussion
The participants
In total, 1,163 women were asked to participate in the study. The consent rate was 86%, resulting in 1,003 participants (Table 1). The main reason why women declined participation was because of language difficulties (59%), followed by lack of interest (20%) or lack of time (17%). Some participants did not answer all the questions and thus the sample size varies slightly by question.
Attitudes towards prenatal examinations
The vast majority of the participants considered examinations aiming to detect fetal abnormalities to be good. On a five-point Likert scale where 1 = “Good” and 5 = “Bad”, 90.7% scored 1–2. Only 1.4% scored 4–5, and 7.9% scored 3, i.e. “Neither good nor bad”. A majority of the women (68.8%) perceived prenatal examinations as calming, and 56.2% stated that it was self-evident to undergo such examinations. However, one fourth (26.8%) perceived prenatal examinations as frightening (Table 2). When the women were asked about their attitudes towards specific prenatal examination methods, 96.9% stated that they were positive towards prenatal ultrasound, whereas the corresponding proportion regarding amniocentesis/CVS was only 42.1%. Regarding FCT and NIPT, the corresponding proportions were similar (78.0% vs. 73.0%, respectively) (Table 3). This is in line with the knowledge that women prefer examinations without risk for the fetus [31]. However, the positive attitude towards NIPT, as well as for FCT in this cohort did not reach the level of ultrasound examination. This may be explained by that ultrasound is appealing also to women who, for various reasons, do not want to perform prenatal chromosomal screening. Furthermore, to view the baby on the screen is a very strong emotional experience for the expectant parents, and is even a facilitator for attachment [32]. Košek et al. recently developed a measure of anxiety due to prenatal diagnostic procedures. They showed that women having an amniocentesis had a higher procedure-induced anxiety than women having an ultrasound examination. However, the women experienced the same level of fear of having an abnormal result [33]. Regarding NIPT, the procedure-induced anxiety will likely be lower than for amniocentesis as it is not associated with any risk for the fetus, but probably higher than for ultrasound examination as having to wait for the result is an anxiety-inducing factor [33].
Awareness and interest regarding NIPT
One of the main purposes of this study was to gain an understanding of how NIPT would be received by Swedish pregnant women as the method was soon to be introduced into Swedish healthcare. In this cohort, 588 out of 983 women (59.8%) stated that they had heard about NIPT previously. The women were asked if they would like to use NIPT if available. On a five-point Likert scale where 5 = “Yes, I am completely sure” and 1 = “No, absolutely not”, 74.0% of the women (n = 723) claimed that they would like to use it, 12.1% women (n = 118) stated that they would not use it, and 13.9% (n = 136) did not know. It is striking that women who had never heard about NIPT stated that they would like to do the test just by hearing about it in the questionnaire. This suggests that the short description, “it is possible to take a blood sample in early pregnancy that with high accuracy can tell if the fetus has a chromosomal abnormality”, which was the only information provided, is very appealing. Previous studies have shown that pregnant women’s interest in NIPT differs greatly between countries, ranging from 51% in the Netherlands [34] to 88% in the UK [20]. The results of the present study are similar to a Californian study including 114 pregnant women, where 71.9% were interested in using NIPT [21].
The women were asked whether they would need information to facilitate their decision about whether or not to undergo NIPT, and although most of the women already seemed to have decided one way or the other, a great majority stated that they would need more information. Of those who stated that they wanted to have the test, 83.5% (n = 599) requested information, whereas the corresponding proportion was significantly lower, 64.1% (n = 75), among the women who did not want the test (p<0.001). This may indicate that women who are against chromosomal screening are more firm in their belief. Not surprisingly, almost all women (91.0%, n = 122) who were uncertain whether they would like to use NIPT stated that they would need information. By far the most requested alternative regarding how to receive information was orally by the midwife, selected by 638 of the 801 women who requested information (79.7%). This puts high demands on the midwives in terms of genetic knowledge and counseling skills, e.g. to describe the relationship between sensitivity/specificity and positive predictive value in an apprehensible fashion, to avoid that women perceive NIPT as a diagnostic test [35]. However the women could choose more than one alternative, and many (n = 392, 48.9%) selected oral in combination with written information. A separate appointment with a doctor or midwife was less requested (n = 187, 23.3%) as was information on the internet (n = 167, 20.8%).
Desired information and willingness to pay regarding NIPT
The women were asked what information they would like from a NIPT analysis, and could score either “Yes” or “No” for each alternative provided. Out of the 859 women who potentially would like to use NIPT, i.e. those who stated that they wanted the test together with the women who were not sure, half (50.4%) stated that they would like to know the fetal sex, 96.3% would like to know if the fetus had Down syndrome, and 98.0% would like to know if the fetus had another, more severe chromosomal abnormality. Additionally, 93.2% would like to receive information about all detectable chromosomal abnormalities (Table 4). A large, recent study of women and health professionals in nine different countries showed that women in general placed the greatest emphasis on comprehensive information and test safety, whereas health professionals placed more emphasis on test accuracy and that the test could be performed in early pregnancy [36]. Similar results were shown in a Dutch study including 507 pregnant women, where the participants were willing to accept a far less accurate test to obtain more information about the fetal chromosome status [37].
Conversely, out of the women in our cohort who would not use NIPT, only 48.0% would like to know if their fetus had Down syndrome. However, considerably more (68.9%) would like to know if the fetus had another, more severe chromosomal abnormality (Table 4). There is an ongoing debate regarding if it is ethically defensible to screen for Down syndrome. In a questionnaire study including 284 people with Down syndrome living in the United States, almost all participants reported that they live happy and fulfilling lives, and that they share similar hopes and dreams as people without the syndrome [38]. However, in a study including mothers of children with Down syndrome, the majority thought NIPT to be a good thing; mainly because detection in early pregnancy would allow for time to prepare to care for a child with the condition [26].
Out of the 859 women that potentially would like to undergo NIPT, 78.1% (n = 671) stated that they would be willing to pay for themselves if NIPT was not covered by the national health insurance. However, most of them (n = 498, 74.2%) were willing to pay €50 to €100, i.e. the lowest price range of the alternatives given, and considerably less than the cost of a commercial NIPT analysis. Approximately one fifth (n = 147, 21.9%) would pay between €200 and €2,000, and a small number were willing to pay as much as €5,000 (n = 5, 0.9%). In a Dutch study, the mean price that participants were willing to pay for NIPT was €169, i.e. close to the €150 that women ≤36 years pay for FCT in the Netherlands [39]. In Sweden, healthcare is generally free of charge, which probably affects the willingness to pay for specific analyses.
Attitudes towards chromosomal abnormalities and self-perceived risk
Almost one third (n = 306, 30.5%) of all women in the cohort stated that it would not matter if their baby was born with a chromosomal abnormality such as Down syndrome, although a number of women wrote comments such as, “I would be sad about the fact that the child would not be healthy, but I would not terminate a pregnancy because of it”, or “it would probably be hard at first, but I would love the child just as much anyway”. Conversely, 44.9% (n = 450) stated that they would react negatively, and 17.9% (n = 180) would find it very negative. No statistical differences were identified between nulli- and multiparas (p = 0.777), or between women who had experienced miscarriages or not (p = 0.382). However, women willing to do NIPT stated that they would react negatively or very negatively to a significantly higher extent than women who would not like to do the test (76.7% vs. 36.3%, p<0.001).
The women were asked about their self-perceived likelihood of having a child with a chromosomal abnormality. On a five-point Likert scale ranging from “Not likely at all” to “Very likely”, 72.8% stated that they thought it was unlikely, whereas 3.6% thought it was likely, and 20.8% stated that they did not know. The results did not differ between women below or above 35 years of age (p = 0.618). The women were asked to specify what they thought was a high probability by selecting an alternative on a scale ranging from 1:1 to 1:20,000. The most frequent answer, selected by 32.5% (n = 224) was 1:200, i.e. the threshold used as high risk in FCT screening in Sweden. However, almost one third (n = 301, 30.4%) answered, “I don’t know”, indicating that they either did not know, or that they did not know how to interpret the values. The challenge of communicating risk has been addressed in previous studies [40], and the development of tools to facilitate this issue has been requested [41]. The women were also asked to specify what they thought was their own probability of having a child with a chromosomal abnormality. After excluding women who had gone through FCT, amniocentesis or CVS (as they would already be aware of their probability), there were 419 women who potentially could have given an answer. However, seven values were missing, and as many as 241 women (57.5%) answered “I don’t know”. Out of the 171 women giving an answer, 50.9% (n = 87) thought their probability was 1:20,000 or 1:10,000. The distribution of all answers is displayed in Fig 1.
The women answered the question by selecting one of the answers displayed on the x-axis. In B, women who had performed the first trimester combined test or invasive testing were excluded.
Decision making regarding prenatal chromosomal screening
The main factor affecting the women’s decision to undergo prenatal chromosomal screening was worry about the baby’s health (n = 799, 82.5%), followed by the urge to have as much information as possible about the fetus (n = 528, 54.5%). Only a small proportion stated that they were affected by expectations from others (n = 25, 2.6%) or the feeling that “everyone else is having such tests” (n = 5, 0.5%). The women could also state another, own option, and 3.5% (n = 35) wrote, “mental preparation” (Table 5). Out of the 118 women who stated that they did not want to use NIPT, 20.3% (n = 24) wrote that nothing influenced their decision as they were already convinced that they did not want to do such tests, and another 38.1% did not choose any of the given alternatives, which further strengthens the hypothesis that the women who not want to perform prenatal chromosomal screening are more convinced about their choice. This is in line with a study that showed that women declining prenatal screening make informed decisions to a higher extent than screening acceptors [30], which could partially be explained by that many women perceive prenatal screenings as routine analyses [42].
When asked about who influences the women’s decision to undergo prenatal chromosomal screening, 95.8% (n = 932) stated that it is their own decision. However, the women could select more than one alternative, and the majority (n = 660, 67.9%) selected themselves together with their partner. Considerably less women stated that they were affected by the midwife or doctor at the maternity clinic (n = 137, 14.1% vs. n = 98, 10.1%, respectively). Hopefully, this reflects that expectant parents feel sufficiently informed to make their own choice and that the health professionals have managed to deliver information about the analyses in an objective manner.
Study strengths and limitations
This study includes a large number of participants who had access to equal maternity care conditions. All data were collected before NIPT was available via national healthcare. The maternity clinics were selected to represent a wide variety in socioeconomic status of the participating women. A limitation of the study is that the questionnaire was only available in Swedish. Although a few non-Swedish speaking women were able to complete the questionnaire with the help of an interpreter, 93 women declined participation because of language difficulties. This was especially a problem in the suburban areas. The study reflects opinions of well-educated pregnant women living in a larger city and can not be generalized to the pregnant population as a whole. However, the large cohort may reflect the views of women living under similar circumstances.
Conclusion
The overwhelming majority of a cohort of 1,003 pregnant women considered examinations aiming to detect fetal abnormalities to be good. Moreover, the majority was positive towards NIPT and would like to use the test if available.
Supporting Information
S1 Questionnaire. English translation of the questionnaire used in the study.
https://doi.org/10.1371/journal.pone.0156088.s002
(PDF)
Acknowledgments
We thank the study participants and the contributing maternity clinics. This research was made possible by a grant from Stockholm County Council as well as a grant to the project Mind the Risk from Riksbankens Jubileumsfond (The Swedish Foundation for Humanities and Social Sciences).
Author Contributions
Conceived and designed the experiments: ES MN PG JW SG EI. Performed the experiments: ES JW SG. Analyzed the data: ES. Contributed reagents/materials/analysis tools: MN SG EI. Wrote the paper: ES MN PG JW SG EI.
References
- 1. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485–7. pmid:9274585.
- 2. Chiu RW, Akolekar R, Zheng YW, Leung TY, Sun H, Chan KC, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. Bmj. 2011;342:c7401. pmid:21224326; PubMed Central PMCID: PMC3019239.
- 3. Sehnert AJ, Rhees B, Comstock D, de Feo E, Heilek G, Burke J, et al. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clinical chemistry. 2011;57(7):1042–9. pmid:21519036.
- 4. Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. American journal of obstetrics and gynecology. 2011;204(3):205 e1–11. pmid:21310373.
- 5. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genetics in medicine: official journal of the American College of Medical Genetics. 2011;13(11):913–20. pmid:22005709.
- 6. Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genetics in medicine: official journal of the American College of Medical Genetics. 2012;14(3):296–305. pmid:22281937; PubMed Central PMCID: PMC3938175.
- 7. Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. American journal of obstetrics and gynecology. 2012;207(5):374 e1–6. pmid:23107079.
- 8. Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, et al. DNA sequencing versus standard prenatal aneuploidy screening. The New England journal of medicine. 2014;370(9):799–808. pmid:24571752.
- 9. Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, et al. Cell-free DNA analysis for noninvasive examination of trisomy. The New England journal of medicine. 2015;372(17):1589–97. pmid:25830321.
- 10. Zhang H, Gao Y, Jiang F, Fu M, Yuan Y, Guo Y, et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2015;45(5):530–8. pmid:25598039.
- 11. Morain S, Greene MF, Mello MM. A new era in noninvasive prenatal testing. The New England journal of medicine. 2013;369(6):499–501. pmid:23862975.
- 12. Mersy E, de Die-Smulders CE, Coumans AB, Smits LJ, de Wert GM, Frints SG, et al. Advantages and Disadvantages of Different Implementation Strategies of Non-Invasive Prenatal Testing in Down Syndrome Screening Programmes. Public health genomics. 2015. pmid:26202817.
- 13. Benn P, Borell A, Chiu R, Cuckle H, Dugoff L, Faas B, et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenatal diagnosis. 2013;33(7):622–9. pmid:23616385.
- 14. Akolekar R, Beta J, Picciarelli G, Ogilvie C, D'Antonio F. Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2015;45(1):16–26. pmid:25042845.
- 15. Wulff CB, Gerds TA, Rode L, Ekelund CK, Petersen OB, Tabor A, et al. Risk of fetal loss associated with invasive testing following combined first-trimester screening for Down syndrome: a national cohort of 147 987 singleton pregnancies. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2016;47(1):38–44. pmid:26581188.
- 16. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet. 1986;1(8493):1287–93. pmid:2423826.
- 17. Simpson JL. Invasive procedures for prenatal diagnosis: any future left? Best practice & research Clinical obstetrics & gynaecology. 2012;26(5):625–38. pmid:22749621.
- 18. Kelly SE, Farrimond HR. Non-invasive prenatal genetic testing: a study of public attitudes. Public health genomics. 2012;15(2):73–81. pmid:22094262.
- 19. Farrell RM, Agatisa PK, Nutter B. What women want: lead considerations for current and future applications of noninvasive prenatal testing in prenatal care. Birth. 2014;41(3):276–82. pmid:24825739; PubMed Central PMCID: PMC4195446.
- 20. Lewis C, Hill M, Silcock C, Daley R, Chitty LS. Non-invasive prenatal testing for trisomy 21: a cross-sectional survey of service users' views and likely uptake. BJOG: an international journal of obstetrics and gynaecology. 2014;121(5):582–94. pmid:24433394.
- 21. Tischler R, Hudgins L, Blumenfeld YJ, Greely HT, Ormond KE. Noninvasive prenatal diagnosis: pregnant women's interest and expected uptake. Prenatal diagnosis. 2011;31(13):1292–9. pmid:22028097; PubMed Central PMCID: PMC3225485.
- 22. Lewis C, Silcock C, Chitty LS. Non-invasive prenatal testing for Down's syndrome: pregnant women's views and likely uptake. Public health genomics. 2013;16(5):223–32. pmid:23886854.
- 23. van Schendel RV, Kleinveld JH, Dondorp WJ, Pajkrt E, Timmermans DR, Holtkamp KC, et al. Attitudes of pregnant women and male partners towards non-invasive prenatal testing and widening the scope of prenatal screening. European journal of human genetics: EJHG. 2014;22(12):1345–50. pmid:24642832; PubMed Central PMCID: PMC4231403.
- 24. de Jong A, Dondorp WJ, de Die-Smulders CE, Frints SG, de Wert GM. Non-invasive prenatal testing: ethical issues explored. European journal of human genetics: EJHG. 2010;18(3):272–7. pmid:19953123; PubMed Central PMCID: PMC2987207.
- 25. Minear MA, Alessi S, Allyse M, Michie M, Chandrasekharan S. Noninvasive Prenatal Genetic Testing: Current and Emerging Ethical, Legal, and Social Issues. Annual review of genomics and human genetics. 2015;16:369–98. pmid:26322648.
- 26. Kellogg G, Slattery L, Hudgins L, Ormond K. Attitudes of mothers of children with down syndrome towards noninvasive prenatal testing. Journal of genetic counseling. 2014;23(5):805–13. pmid:24481673; PubMed Central PMCID: PMC4119092.
- 27. Austin JC. Re-conceptualizing risk in genetic counseling: implications for clinical practice. Journal of genetic counseling. 2010;19(3):228–34. pmid:20119700; PubMed Central PMCID: PMC3706327.
- 28. Slovic P, Finucane ML, Peters E, MacGregor DG. Risk as analysis and risk as feelings: some thoughts about affect, reason, risk, and rationality. Risk analysis: an official publication of the Society for Risk Analysis. 2004;24(2):311–22. pmid:15078302.
- 29.
The Swedish Pregnancy Registry, yearly report 2014 [WWW document]. Available: https://www.medscinet.com/GR/default.aspx [accessed on 5 November 2015].
- 30. van den Berg M, Timmermans DR, ten Kate LP, van Vugt JM, van der Wal G. Informed decision making in the context of prenatal screening. Patient education and counseling. 2006;63(1–2):110–7. pmid:16242899.
- 31. Hill M, Fisher J, Chitty LS, Morris S. Women's and health professionals' preferences for prenatal tests for Down syndrome: a discrete choice experiment to contrast noninvasive prenatal diagnosis with current invasive tests. Genetics in medicine: official journal of the American College of Medical Genetics. 2012;14(11):905–13. pmid:22935718.
- 32. Ekelin M, Crang-Svalenius E, Dykes AK. A qualitative study of mothers' and fathers' experiences of routine ultrasound examination in Sweden. Midwifery. 2004;20(4):335–44. pmid:15571882.
- 33. Kosec V, Nakic Rados S, Gall V. Development and validation of the Prenatal Diagnostic Procedures Anxiety Scale. Prenatal diagnosis. 2014;34(8):770–7. pmid:24676886.
- 34. van Schendel RV, Dondorp WJ, Timmermans DR, van Hugte EJ, de Boer A, Pajkrt E, et al. NIPT-based screening for Down syndrome and beyond: what do pregnant women think? Prenatal diagnosis. 2015;35(6):598–604. pmid:25693726.
- 35. Benn P, Borrell A, Chiu RW, Cuckle H, Dugoff L, Faas B, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenatal diagnosis. 2015;35(8):725–34. pmid:25970088.
- 36. Hill M, Johnson JA, Langlois S, Lee H, Winsor S, Dineley B, et al. Preferences for prenatal tests for Down syndrome: an international comparison of the views of pregnant women and health professionals. European journal of human genetics: EJHG. 2015. pmid:26577044.
- 37. Beulen L, Grutters JP, Faas BH, Feenstra I, Groenewoud H, van Vugt JM, et al. Women's and healthcare professionals' preferences for prenatal testing: a discrete choice experiment. Prenatal diagnosis. 2015;35(6):549–57. pmid:25644120.
- 38. Skotko BG, Levine SP, Goldstein R. Self-perceptions from people with Down syndrome. American journal of medical genetics Part A. 2011;155A(10):2360–9. pmid:21910246; PubMed Central PMCID: PMC3740159.
- 39. Verweij EJ, Oepkes D, de Vries M, van den Akker ME, van den Akker ES, de Boer MA. Non-invasive prenatal screening for trisomy 21: what women want and are willing to pay. Patient education and counseling. 2013;93(3):641–5. pmid:24011429.
- 40. Pighin S, Bonnefon JF, Savadori L. Overcoming number numbness in prenatal risk communication. Prenatal diagnosis. 2011;31(8):809–13. pmid:21692090.
- 41. Keller C, Siegrist M. Effect of risk communication formats on risk perception depending on numeracy. Medical decision making: an international journal of the Society for Medical Decision Making. 2009;29(4):483–90. pmid:19525484.
- 42. Press N, Browner CH. Why women say yes to prenatal diagnosis. Social science & medicine. 1997;45(7):979–89. pmid:9257391.